What are the possible causes of hiccups in a 56-year-old male with acute myeloid leukemia receiving day 2 of a 7 + 3 chemotherapy regimen (continuous cytarabine infusion and anthracycline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Possible Causes of Hiccups in This Clinical Context

In a 56-year-old male with AML on day 2 of 7+3 chemotherapy, the most likely cause of hiccups is dexamethasone used as part of antiemetic prophylaxis, though other chemotherapy-related and disease-related factors must also be considered.

Primary Culprit: Corticosteroid Antiemetics

The most common iatrogenic cause of hiccups during chemotherapy is dexamethasone, which is routinely prescribed as antiemetic prophylaxis during intensive chemotherapy 1, 2. Studies demonstrate that:

  • Male patients are disproportionately affected by chemotherapy-induced hiccups, with up to 97.4% of hiccup cases occurring in men receiving platinum-based regimens with dexamethasone 2
  • Dexamethasone-induced hiccups typically begin within 24-48 hours of chemotherapy initiation 1
  • Discontinuation of dexamethasone in subsequent cycles eliminates hiccups in approximately 90% of cases 2

The timing (day 2) and patient demographics (56-year-old male) in this case strongly suggest dexamethasone as the primary etiology.

Chemotherapy-Related Causes

Cytarabine Toxicity

While cytarabine is a core component of 7+3 induction 3, it rarely causes hiccups directly. However, be vigilant for:

  • Cerebellar syndrome: Typically manifests 2-5 days after high-dose cytarabine with dizziness, ataxia, dysarthria, and nausea/vomiting 4
  • Risk factors include age >40 years, renal impairment, and high cumulative doses 4
  • Standard-dose cytarabine (100-200 mg/m²) used in 7+3 carries lower risk than high-dose regimens 3

Anthracycline Component

The anthracycline (daunorubicin or idarubicin) in 7+3 is not typically associated with hiccups 3.

NK1 Receptor Antagonists

If aprepitant or fosaprepitant was used for antiemetic prophylaxis, this significantly increases hiccup risk:

  • Concomitant aprepitant/fosaprepitant increases odds of hiccups (OR: 2.23) 5
  • However, aprepitant does not appear to be a major risk factor with high-dose platinum regimens when properly studied 6

Disease-Related Causes

Metabolic Derangements

AML patients receiving intensive chemotherapy are at high risk for:

  • Tumor lysis syndrome: Monitor uric acid, phosphate, potassium, calcium, and renal function 3
  • Electrolyte abnormalities: Particularly hyponatremia, hypocalcemia, hypomagnesemia
  • Uremia: From renal dysfunction secondary to tumor lysis or drug toxicity

CNS Involvement

Consider CNS leukemia, particularly given:

  • Monocytic differentiation (M4/M5 morphology)
  • WBC >40,000/mcL at diagnosis
  • Extramedullary disease 3

If neurologic signs/symptoms are present, obtain brain MRI with contrast and consider lumbar puncture 3.

Infection/Sepsis

Day 2 is early for neutropenic fever, but consider:

  • Baseline infection present at diagnosis
  • Rapidly developing neutropenia with pre-existing colonization
  • Fungal infections (though typically occur later in treatment course) 7

Gastrointestinal Pathology

  • Gastric distension from nausea/vomiting
  • Esophageal irritation from mucositis (though typically develops later)
  • Hepatomegaly from leukemic infiltration causing diaphragmatic irritation

Diagnostic Approach

Immediate assessment should include:

  1. Medication review: Confirm dexamethasone dosing and timing; identify any NK1 antagonist use
  2. Metabolic panel: Electrolytes, renal function, calcium, magnesium, phosphate, uric acid
  3. Neurologic examination: Assess for cerebellar signs (nystagmus, dysmetria, ataxia, slurred speech) 7, 4
  4. Infection workup: If febrile or clinically unstable
  5. Consider imaging: Brain MRI if any neurologic symptoms; chest X-ray if respiratory symptoms

Management Strategy

First-Line Intervention

Discontinue or reduce dexamethasone if hiccups are persistent and distressing 1, 2:

  • This eliminates hiccups in ~90% of cases 2
  • Monitor for breakthrough nausea/vomiting, which may increase but can often be managed with alternative antiemetics 1
  • Consider 5-HT3 antagonists alone or with olanzapine as alternative antiemetic strategy 8

Symptomatic Treatment

If dexamethasone cannot be discontinued or hiccups persist:

  • Chlorpromazine: Most evidence-based pharmacologic option
  • Baclofen: GABA-B agonist, effective for persistent hiccups
  • Metoclopramide: Particularly if gastroparesis suspected
  • Gabapentin: Alternative for refractory cases

Address Underlying Causes

  • Correct electrolyte abnormalities aggressively
  • Optimize tumor lysis prophylaxis (hydration, allopurinol/rasburicase) 7
  • If cerebellar toxicity develops, discontinue cytarabine immediately and do not rechallenge 7

Critical Pitfalls to Avoid

  1. Do not automatically attribute hiccups to chemotherapy agents when corticosteroids are the more likely culprit 1
  2. Do not overlook metabolic derangements in the setting of intensive chemotherapy and high tumor burden
  3. Do not miss early cerebellar toxicity - perform neurologic assessments before each cytarabine dose 7
  4. Do not delay workup for CNS leukemia if any neurologic symptoms are present 3
  5. Monitor for concurrent symptoms - the inverse correlation between hiccups and nausea/vomiting suggests dexamethasone etiology 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.